Comparison of dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis

This publication has 19 references indexed in Scilit:

• Effectiveness, safety and cost analysis of dalbavancin in clinical practice
  European Journal of Hospital Pharmacy, 2020
• Dalbavancin and telavancin in the treatment of infective endocarditis: a literature review
  International Journal of Antimicrobial Agents, 2020
• Prevalence of Hospital-Associated Disability in Older Adults: A Meta-analysis
  Journal of the American Medical Directors Association, 2020
• Dalbavancin use in an academic medical centre and associated cost savings
  International Journal of Antimicrobial Agents, 2019
• On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections
  Journal of Antimicrobial Chemotherapy, 2019
• Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis
  New England Journal of Medicine, 2019
• Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections
  Expert Opinion on Drug Metabolism & Toxicology, 2017
• Assessing the nutritional status of hospitalized elderly
  Clinical Interventions in Aging, 2017
• 2015 ESC Guidelines for the management of infective endocarditis
  European Heart Journal, 2015
• Selection of a Surrogate Agent (Vancomycin or Teicoplanin) for Initial Susceptibility Testing of Dalbavancin: Results from an International Antimicrobial Surveillance Program
  Journal of Clinical Microbiology, 2006